Jazz Pharmaceuticals JAZZ Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's increase (decrease) in accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's increase (decrease) in accounts receivable?
- Jazz Pharmaceuticals (JAZZ) reported increase (decrease) in accounts receivable of $6.5M in Q1 2026.
- How has Jazz Pharmaceuticals's increase (decrease) in accounts receivable changed year-over-year?
- Jazz Pharmaceuticals's increase (decrease) in accounts receivable increased by 109.8% year-over-year, from -$66M to $6.5M.
- What is the long-term trend for Jazz Pharmaceuticals's increase (decrease) in accounts receivable?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's increase (decrease) in accounts receivable has grown at a 1.6% compound annual growth rate (CAGR), from $99.62M to $106.28M.
- What does increase (decrease) in accounts receivable mean?
- The change in the amount of money customers owe the company for past purchases.
- How do you interpret increase (decrease) in accounts receivable?
- An increase suggests slower cash collection or rising sales, while a decrease indicates improved collection efficiency or declining sales.
- How does increase (decrease) in accounts receivable compare across companies?
- Standard across all industries; peers with similar payment terms should show comparable trends relative to revenue growth.